ORSERDUTM (ELACESTRANT)
Publications
Journal of Clinical Oncology (2022): Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology (2021): Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Presentations
Nothing found.
ELZONRIS® (TAGRAXOFUSP)
Publications
Journal of Clinical Oncology (2022): Long-Term Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Presentations
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. EHA 2018.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Relapsed/Refractory CMML. EHA 2018.
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), Kills Plasmacytoid Dendritic Cells (pDCs) from Systemic Sclerosis Patients. EULAR 2018.
Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2017.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis. ASH 2017.
Results From Ongoing Phase 1/2 Trial of SL-401 as Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD). ASH 2017.
SL-801
Nothing found.
SL-701
Nothing found.